Debt-to-equity of ABVC BIOPHARMA, INC. from 31 Dec 2016 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
ABVC BIOPHARMA, INC. quarterly Debt-to-equity in % history and change rate from 31 Dec 2016 to 30 Sep 2025.
  • ABVC BIOPHARMA, INC. Debt-to-equity for the quarter ending 30 Sep 2025 was 106%, a 73% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

ABVC BIOPHARMA, INC. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 106% -283% -73% 30 Sep 2025
Q2 2025 176% -15% -8% 30 Jun 2025
Q1 2025 265% +12% +4.9% 31 Mar 2025
Q4 2024 414% +139% +51% 31 Dec 2024
Q3 2024 389% +148% +61% 30 Sep 2024
Q2 2024 192% -98% -34% 30 Jun 2024
Q1 2024 253% +129% +105% 31 Mar 2024
Q4 2023 274% +195% +246% 31 Dec 2023
Q3 2023 241% +181% +302% 30 Sep 2023
Q2 2023 289% +234% +423% 30 Jun 2023
Q1 2023 124% +37% +43% 31 Mar 2023
Q4 2022 79% -46% -37% 31 Dec 2022
Q3 2022 60% -133% -69% 30 Sep 2022
Q2 2022 55% -435% -89% 30 Jun 2022
Q1 2022 86% -671% -89% 31 Mar 2022
Q4 2021 125% -4557% -97% 31 Dec 2021
Q3 2021 193% +1245% 30 Sep 2021
Q2 2021 490% +2227% 30 Jun 2021
Q1 2021 758% +1566% 31 Mar 2021
Q4 2020 4682% +5114% 31 Dec 2020
Q3 2020 -1052% -759% -259% 30 Sep 2020
Q2 2020 -1737% -1506% -654% 30 Jun 2020
Q1 2020 -808% -596% -281% 31 Mar 2020
Q4 2019 -432% -222% -106% 31 Dec 2019
Q3 2019 -293% -68% -30% 30 Sep 2019
Q2 2019 -230% +15% +6% 30 Jun 2019
Q1 2019 -212% +18% +7.7% 31 Mar 2019
Q4 2018 -209% -2% -0.8% 31 Dec 2018
Q3 2018 -225% -95% -74% 30 Sep 2018
Q2 2018 -245% -143% -140% 30 Jun 2018
Q1 2018 -230% -128% -126% 31 Mar 2018
Q4 2017 -208% -74% -55% 31 Dec 2017
Q3 2017 -129% 30 Sep 2017
Q2 2017 -102% 30 Jun 2017
Q1 2017 -102% 31 Mar 2017
Q4 2016 -134% 31 Dec 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.